Zacks: Analysts Set $6.00 Target Price for HTG Molecular Diagnostics, Inc. (HTGM)

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) has been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Brokerages have set a one year consensus price target of $6.00 for the company and are expecting that the company will post ($0.41) EPS for the current quarter, according to Zacks. Zacks has also assigned HTG Molecular Diagnostics an industry rank of 171 out of 265 based on the ratings given to related companies.

HTGM has been the subject of several analyst reports. Zacks Investment Research cut shares of HTG Molecular Diagnostics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 15th. ValuEngine upgraded shares of HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of HTG Molecular Diagnostics in a research report on Tuesday, September 12th.

HTG Molecular Diagnostics (NASDAQ:HTGM) traded down $0.10 on Friday, hitting $2.03. 345,708 shares of the company traded hands, compared to its average volume of 520,200. HTG Molecular Diagnostics has a 1 year low of $1.20 and a 1 year high of $13.25.

A number of large investors have recently bought and sold shares of HTGM. Granahan Investment Management Inc. MA raised its position in HTG Molecular Diagnostics by 488.3% during the third quarter. Granahan Investment Management Inc. MA now owns 416,608 shares of the medical research company’s stock worth $708,000 after acquiring an additional 345,798 shares during the period. Vanguard Group Inc. raised its position in HTG Molecular Diagnostics by 38.9% during the second quarter. Vanguard Group Inc. now owns 135,234 shares of the medical research company’s stock worth $359,000 after acquiring an additional 37,841 shares during the period. Finally, UBS Group AG acquired a new position in HTG Molecular Diagnostics during the first quarter worth $137,000. Institutional investors own 15.45% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/02/zacks-analysts-set-6-00-target-price-for-htg-molecular-diagnostics-inc-htgm.html.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Get a free copy of the Zacks research report on HTG Molecular Diagnostics (HTGM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply